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Abstract: Ample evidence supports the use of statin therapy for secondary prevention in patients
with a history of atherosclerotic cardiovascular disease (ASCVD), but evidence is wanting in the case
of primary prevention, low-risk individuals, and elderly adults 65+. Statins are effective in lowering
low-density lipoprotein (LDL), which has long been a target for treatment decisions. We discuss the
weakening dependence between cholesterol levels and mortality as a function of age and highlight
recent findings on lipoprotein subfractions and other superior markers of ASCVD risk. The efficacy of
statins is compared for distinct subsets of patients based on age, diabetes, ASCVD, and coronary artery
calcium (CAC) status. Most cardiovascular risk calculators heavily weight age and overestimate one’s
absolute risk of ASCVD, particularly in very old adults. Improvements in risk assessment enable
the identification of specific patient populations that benefit most from statin treatment. Derisking
is particularly important for adults over 75, in whom treatment benefits are reduced and adverse
musculoskeletal effects are amplified. The CAC score stratifies the benefit effect size obtainable with
statins, and forms of coenzyme Q are discussed for improving patient outcomes. Robust risk estimator
tools and personalized, evidence-based approaches are needed to optimally reduce cardiovascular
events and mortality rates through administration of cholesterol-lowering medications.
Keywords: cardiovascular disease; statins; primary prevention; geriatrics; risk biomarkers;
cardiovascular risk calculators; low-density lipoprotein cholesterol; lipoprotein subfractions; coronary
artery calcification; coenzyme Q
1. Introduction
Atherosclerotic cardiovascular disease (ASCVD), a leading cause of morbidity, accounts for 1 in
3 deaths in U.S. adults [1]. Statin drugs, which inhibit the body’s endogenous synthesis of cholesterol,
have become a mainstay in the primary prevention and treatment of existing ASCVD and are now
one of the most commonly prescribed drugs in the world [2]. From 2002 to 2013, statin use among US
adults 40 years and older almost doubled, from 22 to 39 million adults, or 28% of the population [3].
The Medical Expenditure Panel Survey found that statin use for primary ASCVD prevention in adults
80 years and older increased four-fold, from 9% in 1999 to 34% in 2012 [4]. The 2013 American College
of Cardiology/American Heart Association (ACC/AHA) guidelines for the management of blood
cholesterol identified 13 million Americans as newly eligible for consideration statin therapy based on a
10-year ASCVD risk ≥7.5%, which is a lower threshold compared to other international guidelines [5,6].
Given the potential adverse effects of statin use, recent meta- and post-hoc analyses have attempted to
address whether available clinical evidence supports such widespread use, particularly in low-risk
individuals [7].
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Early statin trials excluded elderly patients, and less evidence exists overall for the efficacy of statins
in older adults [8]. While no randomized controlled trials (RCTs) have been conducted using statins in
patients older than 80 years at baseline, the independent STAREE (NCT02099123) and PREVENTABLE
(NCT04262206) trials are currently assessing high intensity statin therapy compared to placebo in adults
70+ and 75+, respectively. Most meta-analyses of statin use to date have included participants for both
primary and secondary prevention, with fewer adults over 65 being represented [2,9,10]. To balance
the potential benefits and harms from statin therapy, efficacy must be compared across different patient
groups of varying cardiovascular risk [11]. In this review, we discuss the role of cholesterol in mortality
and the efficacy of statins as a function of age and other determinants of ASCVD risk. Patients with
no history of ASCVD account for most of the recent increase in statin use [2], for which the decision
to treat has rested heavily on the accuracy of evolving ASCVD risk calculators [12]. The totality of
evidence reveals that the benefit effect size obtained from statin treatment is linked to patient age as
well as the presence of strong ASCVD risk factors. While the relationship between serum cholesterol
and health outcomes is complicated, a new assortment of cardiovascular risk markers has emerged
for determining who best benefits from lipid-lowering treatment. These observations should serve to
guide the development of evidence-based recommendations for clinical practice.
2. Potential for Adverse Effects
The most common adverse effect of statins are musculoskeletal events including myopathy,
myalgias, muscle weakness, arthropathies, and, rarely, rhabdomyolysis [13–15]. Estimates of the
number needed to harm (NNH) in retrospective studies have ranged from 19 to 47 for musculoskeletal
disorders [7,16,17], and statins markedly increase the risk of myopathy [odds ratio (OR): 2.63,
95% confidence interval (CI): 1.50–4.61] [18]. A recent analysis considered 60,455 military adults in
the TRICARE medical program and propensity matched statin users with nonusers [19]. The statin
users (72% used simvastatin) were observed to have a higher likelihood of back disorder diagnosis
(OR: 1.27, 95% CI: 1.19–1.36, NNH = 17 at 4 years). The odds ratio increased to 1.47 when the cohort
was restricted to users of statins for more than two years or to high-intensity statin users vs. nonusers.
A case of rhabdomyolysis was recently reported when canagliflozin was administered to a 5-year
rosuvastatin user [20]. Canagliflozin is a diabetes drug and transport inhibitor that enhances statin
absorption; the patient’s plasma rosuvastatin concentration was 15-fold higher than expected for a
40 mg dose, and the case resolved once the two drugs were stopped. While high-intensity statins
can be avoided to reduce the severity of adverse effects, muscle symptoms are also reported with
moderate-intensity therapy [14]. Muscle weakness and pain pose a particular problem for the elderly,
in whom statins might contribute to deconditioning, frailty, and falls [21].
Analysis of medical claims data for the entire Austrian population (n = 7,897,449) recently revealed
a dose-dependent response in the association of statin use with osteoporosis [22]. Low-dose treatment
(10 mg/day) with lovastatin, pravastatin, simvastatin, or rosuvastatin was observed to decrease risk.
However, for each of six statins osteoporosis diagnosis increased with dosage and was overrepresented
in 60 and 80 mg/d simvastatin [odds ratios (ORs): 1.64 and 3.30], 40 mg/d rosuvastatin (OR: 2.04,
95% CI: 1.31–3.18), and 20, 40, 60 and 80 mg/d atorvastatin (ORs: 1.35, 1.78, 2.12 and 3.14). Interestingly,
elevated osteoporosis risk was primarily observed for adults 60 and younger and was more pronounced
in females. Sex hormones, which are made from cholesterol, decline with age and correlate with
osteoporosis, and statins have been shown to reduce plasma levels of estradiol and testosterone [22].
As noted in a 2012 Food and Drug Administration warning, statin use carries a modest increase in
the relative risk (RR) of new-onset type 2 diabetes [7,23]. Individual statins have been found to increase
blood glucose, reduce insulin secretion and/or decrease insulin sensitivity [24–26]. Meta-analysis of
20 observational studies found that long-term statin use increases the risk of developing incident
diabetes relative to nonusers (RR: 1.44, 95% CI: 1.31–1.58) [27]. High potency statins had the highest risk
(rosuvastatin, RR: 1.61, 95% CI: 1.30−1.98). A 14-year retrospective study of 471,250 elderly patients in
Ontario calculated the 1-year NNH for atorvastatin, rosuvastatin, and simvastatin (NNH: 172, 210,
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and 363, respectively) [24]. A Women’s Health Initiative study of postmenopausal women (ages 50–79)
estimated an NNH = 44 (95% CI: 35−60) for an additional case of diabetes over three years of statin
therapy [18]. While the molecular mechanism of diabetogenic action remains unclear [26], new data
have shown the hydrophilic statins (rosuvastatin and pravastatin) to increase insulin resistance to a
greater degree than lipophilic statins [28].
3. Cholesterol Levels and Clinical Outcomes
3.1. Low-Density Lipoprotein and Total Cholesterol
Plasma low-density lipoprotein cholesterol (LDL-C) has been a principal target of cholesterol-
lowering therapy for the past three decades, and statins are effective in lowering LDL-C to reduce
ASCVD. Data on the relationship between LDL-C and all-cause and cardiovascular mortality rates,
however, reveal a paradoxical association. Ravnskov et al. conducted a systematic review of 19 clinical
studies involving 68,094 patients 60 years or older [29]. In 16 different cohorts accounting for 92%
of participants, an inverse association was found between LDL and all-cause mortality, with a mean
hazard ratio (HR) = 0.54 for the highest vs. lowest quartile LDL-C. Studies reporting cardiovascular
mortality did not find an overall association with LDL [29], except for one study which measured
deaths in each LDL quartile, observing an almost U-shaped dependence with the highest risk in the
lowest LDL quartile [30]. More recently, a population study of 262,391 Korean adults over 40 who did
not use statins revealed that changes in total cholesterol (TC) within a two-year period increase the risk
of subsequent all-cause mortality relative to those who maintained levels in the second tertile [31].
Among the elderly, frailty and poor health status likely contribute to increased risk of death in those
with low cholesterol. TC levels are known to decline in the last stages of life in statin users and
nonusers [32,33], and low cholesterol can be a marker of severe diseases such as cancer [34].
Using LDL-C as an ASCVD predictor is problematic for a number of reasons. LDL was dropped
from the 2008 Framingham calculator for measuring one’s 10-year ASCVD risk because it did not
improve the model fit [35]. While laboratory tests now exist for direct measurement of LDL plasma
concentration, LDL-C is traditionally calculated using the Friedewald equation (Equation (1)) developed
in the 1960s, which is a function of high-density lipoprotein cholesterol (HDL-C) [36]:






Calculated LDL-C measurements rely on the assumption that the ratio of triglycerides to very
low-density lipoprotein (VLDL) is five, but this ratio actually varies between individuals from 2 to
15 [37]. An adaptable equation, LDL-CN, has since been developed that estimates an individual’s
triglycerides:VLDL ratio in order to better approximate directly measured LDL in patients with
triglycerides < 400 mg/dL [37]. LDL-CN has been shown to be more accurate (range, 87–94%)
than Friedewald (range, 71–93%) in both fasting and non-fasting samples [38]. In settings where
LDL < 70 mg/dL and triglycerides were 200–399 mg/dL, LDL-CN is far more accurate (range, 82–94%)
than Friedewald (range, 37–96%).
3.2. Lipoprotein Subfractions
While the bulk of clinical studies have employed traditionally calculated LDL-C (mass/volume),
the number of lipoprotein particles correlates better with ASCVD than the overall mass
concentration [39]. A single apolipoprotein B is responsible for organizing the lipids within an
LDL particle, making plasma levels of apolipoprotein B indicative of LDL particle number [40,41].
In 11,186 JUPITER trial participants with LDL-C < 130 mg/dL, baseline apolipoprotein B and LDL
particle number but not LDL-C were observed to correlate with first major adverse cardiovascular event
(MACE), though a correlation was observed with on-treatment LDL-C levels in the statin users [42].
Similarly, baseline and on-statin HDL particle number (HDL-P) was shown to be the strongest of
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four HDL-related predictors for ASCVD [43]. In the Dallas Heart Study, HDL-P but not HDL-C was
found to inversely associate with coronary heart disease (CHD) in Black participants [44]. Measuring
subfractions of LDL particles based on size is yet another means of getting at particle abundance.
For individuals with the same LDL-C, the amount of small dense LDL (sdLDL) particles in proportion
to large, buoyant LDL (lbLDL) correlates positively with the number of particles and one’s ASCVD
risk [45,46]. Genetic variation in sdLDL metabolism has been associated with CHD, and sdLDL levels
are a strong predictor of CHD (HR: 1.51 highest/lowest quartile, 95% CI: 1.21–1.88), even when LDL-C
levels are low [47].
4. Accuracy of Cardiovascular Risk Calculators: The Pooled Cohort Equations
Available instruments for estimating a patient’s 10-year risk of first cardiovascular event
vary widely in their predictions and application, and are often insufficiently reported [6,48,49].
The Framingham total cardiovascular risk, last updated in 2008, is still recommended by the
Canadian Cardiovascular Society [40], which recommends pharmacotherapy for individuals with
a risk score ≥ 10% and LDL-C ≥ 3.5 mmol/L. Since the 2013 update, the ACC/AHA guidelines
have de-emphasized LDL targets for cholesterol therapy, favoring a reliance on risk estimation
in low to intermediate-risk individuals. In conjunction with development of the 2013 ACC/AHA
guidelines, a new heretofore unpublished estimator tool, known as the pooled cohort equations (PCEs),
was created that replaced the Framingham score in the U.S. as the only calculator derived from U.S.
populations [50–52].
Independent analyses were quick to show that the PCEs overestimate an individuals’ risk up to
two or more times the actual rate of ASCVD events observed in different validation cohorts [53–59].
In so doing, the 2013 ACC/AHA guidelines made nearly half of U.S. adults and up to 87% of men aged
60–75 eligible for statin treatment [12]. Importantly, the PCEs and other risk calculators heavily weigh
age as a determining factor [6]. Most older patients, especially those over 75, exceed the 7.5% 10-year
ASCVD risk threshold for treatment despite the absence of dyslipidemia, diabetes, hypertension,
or smoking [60,61]. Based on the totality of evidence, the U.S. Preventive Services Task Force has
recommended raising the 10-year risk threshold for moderate-intensity statin treatment from 7.5% to
10% for adults aged 40–75 with no history of ASCVD [61].
Various problems have been noted with the derivation of the 2013 PCEs. The patient data set
underrepresented Black adults, and model overfitting resulted in extreme risk estimates relative to
white adults with the same risk factors [58]. The data set also did not reflect modern U.S. society,
with most patient cohorts accrued from the 1960s through 1980s in addition to the original Framingham
study of 1948 [54]. Yadlowsky et al. recently completed a rigorous statistical analysis of the 2013 PCEs
and found that they violate the Cox proportional hazards assumption [58]. Using updated statistical
methods and incorporating data from modern cohorts, the authors were able to derive a revised
set of equations, which resulted in 12 million fewer U.S. adults exceeding the 7.5% risk treatment
threshold. Analogously, a New Zealand population study using the PREDICT cohort of primary care
patients aged 30–74 successfully replaced the PCE equations by adding variables for socioeconomic
deprivation and self-identified ethnicity, which were both shown to be independent predictors [59].
The equation risk predictions closely matched the observed five-year rates of cardiovascular disease.
However, the same equations progressively lost accuracy when applied to very old adults over 75 [62].
The adoption of updated risk calculators based on relevant cohort data will be needed in future clinical
practice to maximize the benefits and minimize adverse events associated with statin therapy.
There are other areas for improvement in the PCEs, such as including chronic kidney disease,
a high-risk condition [51]. Central obesity is also a well-known contributing factor in ASCVD, yet it is
not accounted for in the Framingham or 2013 ACC/AHA risk calculators [52]. While body mass index
(BMI) did not improve model performance in the Framingham calculator [35], waist-to-hip ratio and
the conicity index, also a function of waist circumference, have since emerged as superior predictors of
ASCVD risk across nationalities, especially in women [63–65]. Lastly, the risk calculators use TC as an
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independent variable, but mortality is a non-monotonic function of TC whose shape varies with sex
and age [66,67]. A recent prospective study of 12,815,006 Korean adults found U-shaped curves of
varying slope for all-cause mortality as a function of TC across 12 different age and sex groups [67].
In each of the six age groups spanning 18–99 years, mortality decreased steeply (13–34%) for each
mmol/L (39 mg/dL) increase in the TC range < 200 mg/dL. For TC ≥ 200 mg/dL, there was a more
modest increase in mortality of 3–14% per mmol/L. Associations between mortality and TC were
steepest in age groups 35–44, 45–54, and 55–64, especially in men. These findings, together with the
overestimation of ASCVD risk, help illustrate the shortcomings of relying on simplistic risk calculators
to make treatment decisions [6,48,59].
5. Methodology
Given the interaction between cholesterol levels, mortality, and age, we reviewed the current
literature for available evidence on the benefits of statin treatment in distinct patient groups (stratified by
age group, primary vs. secondary prevention, diabetes and coronary calcium status). Research articles
were identified for examination by searching the MEDLINE database. RCTs, non-randomized
retrospective and prospective observational studies, and meta-analyses were assessed primarily
involving study populations greater than 10,000. Clinical studies and meta-analyses that treated
primary and secondary prevention patients as a single cohort were excluded. Studies of significant
interest are summarized in Table 1.
Table 1. Large-scale clinical studies of significant interest: role of lipid levels, treatment intervention,
and biomarkers in distinct patient groups.
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Table 1. Cont.
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Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcification; CHD, coronary
heart disease; ERFC, Emerging Risk Factors Collaboration; HDL, high-density lipoprotein cholesterol; HR, hazard
ratio; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; NNT, number needed
to treat; Q4, highest quartile; SIDIAP, Information System for the Development of Research in Primary Care; TC,
total cholesterol.
6. Efficacy of Statin Treatment in the Elderly
6.1. Primary Prevention of ASCVD
Ponce et al. performed a comprehensive meta-analysis of 23 RCTs comprising 60,194 patients
aged 65+ [72]. Cohort data was collated for each of five patient groups: ages 65–75, ages 75 and
over, patients with diabetes, patients without diabetes, and patients with hypertension. For primary
prevention in those with no history of ASCVD, statin use was found to reduce the risk of coronary
artery disease [CAD; RR: 0.79, 95% CI: 0.68–0.91] and myocardial infarction (RR: 0.45, 95% CI: 0.31–0.66)
relative to placebo in all patient groups. However, Forest plot analysis revealed that statins did not
significantly reduce the risk of heart failure (RR: 1.04, 95% CI: 0.80–1.35), all-cause mortality (RR: 0.95,
95% CI: 0.84–1.07), or cardiovascular mortality (RR: 1.01, 95% CI: 0.83–1.24) overall or in any patient
group [72]. The one RCT of adults ≥75 reported an increase in all-cause mortality for 40 mg/day
pravastatin vs. usual care (HR: 1.34, 95% CI: 0.98–1.84) [73].
Other meta-analyses of primary prevention in the elderly have similarly reported statistically
significant RR reductions for ASCVD events but not mortality rates. A meta-analysis of JUPITER and
HOPE-3 cohorts aged 65–69 and 70+ by Ridker et al. found non-significant reductions in all-cause
mortality [74]. An earlier meta-analysis was performed of 24,674 adults 65+ spanning 8 RCTs as a single
cohort (mean age 73 ± 2.9 years) [75]. Statins significantly reduced the rate of myocardial infarction
and stroke but not all-cause or cardiovascular mortality. These findings support the conclusion that
the benefits of statin therapy are less than maximal in elderly (65+) patients for primary prevention.
The weakening dependence of mortality on cholesterol levels at ages over 60 is one explanation for the
abatement of statins in extending elderly lifespan [29,67].
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6.2. Primary Prevention with Diabetes
Limited placebo-controlled RCT data is available for elderly patients with diabetes and very old
adults aged 75+ [72]. Ramos et al. conducted a retrospective study of 46,864 participants 75 years and
older with no history of ASCVD for a median follow-up of 5.6 years [69]. To prevent survivor bias
and covariate measurement bias, a new-user study design was employed in which new statin users
were selected for rather than all statin users. A Cox proportional hazards model was used to calculate
the HRs of statin use for outcome events. In patients with diabetes aged 75–84, statins were modestly
effective in reducing ASCVD [HR: 0.76, 95% CI: 0.65–0.89; 1-year number needed to treat (NNT): 164]
and all-cause mortality (HR: 0.84, 95% CI: 0.75–0.94; NNT: 306). The reduction in ASCVD began to
lose statistical significance at age 85 and disappeared completely at age 92. The protective effect of
statins against all-cause mortality began to lose significance at age 82 in patients with diabetes and
disappeared definitively at age 88. Remarkably, in patients without diabetes, statins did not reduce the
risk of ASCVD, stroke, CHD, or all-cause mortality for the age groups 75–84 and 85+. The authors
went on to point out that under current cholesterol guidelines, most of the population was eligible for
statin treatment, having a 10% risk of ASCVD at 10 years [69].
6.3. Secondary Prevention of ASCVD
The meta-analysis by Ponce et al. also assessed the effect of statins in the treatment of patients
diagnosed with clinically significant ASCVD [72]. RCTs were collected for two patient populations,
adults aged 65–75 and patients without diabetes. In contrast to primary prevention, high-certainty
evidence was obtained for the use of statins in adults 65 and over for secondary prevention of ASCVD.
Compared to placebo, statins significantly decreased the risk of all-cause mortality (RR: 0.80, 95% CI:
0.73–0.89), cardiovascular mortality (RR: 0.68, 95% CI: 0.58–0.79), CAD (RR: 0.68, 95% CI: 0.61–0.77),
and myocardial infarction (RR: 0.68, 95% CI: 0.59–0.79). However, evidence was less conclusive for
heart failure (RR: 0.79, 95% CI: 0.59–1.06) and stroke (RR: 0.90, 95% CI: 0.79–1.02). No separate data on
subgroups, such as those specifically over 75 years of age or patients with type 2 diabetes, was available
from the eight trials reviewed.
In 2020, a meta-analysis was performed based on 17 RCTs in elderly patients 65+ for primary or
secondary prevention [76]. The substantial statin benefits obtained for secondary prevention closely
match the findings of Ponce et al. for ASCVD events and mortality rate. Also in agreement with
Ponce et al., in primary prevention statins were observed to significantly reduce the rate of myocardial
infarction but not all-cause or cardiovascular mortality [76]. Despite this abundance of evidence from
RCTs, two retrospective propensity score-matched studies in narrow populations recently reported
reductions in all-cause mortality/ASCVD events in primary prevention adults aged 75+. A study of US
veterans (97% men, 91% white) found HRs of 0.75/0.92 [77], while a study of 1278 Koreans found HRs
of 0.56/0.59 [78].
7. Coronary Artery Calcification for Guiding Treatment Decisions
Robust measures of ASCVD risk are needed to guide treatment decisions in low-risk primary
prevention patients. The severity of CAD and plaque formation can be assessed quantitatively based
on the level of coronary artery calcification (CAC) in a computed tomography scan. The CAC score
has been shown to be a strong independent risk factor for ASCVD and all-cause mortality [79].
A meta-analysis was previously conducted of 49 studies involving 85,000 patients [80]. During a
mean follow-up period of 50 months, 0.47% of patients with no CAC suffered a cardiovascular event,
compared to 4.1% of patients with CAC, highlighting the metric’s negative predictive power. In a
recent retrospective study of 22,346 adults ages 30–49, CAC was present in 34% of patients, of which
7% had CAC >100 [81]. The latter had a 10-fold higher CHD mortality rate compared to those with
no CAC. Of the CHD deaths reported in the study period (mean follow-up, 12.7 years), 68% were in
individuals who had CAC at baseline.
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Mitchell et al. completed a retrospective cohort study of 13,644 consecutive subjects over the
age of 18 who underwent CAC scoring, assessing the impact of statin use on first observed MACE in
the 9.4-year follow-up period [71]. Outcomes were stratified by baseline CAC score and HRs were
determined separately for all statin users (n = 6886) and compliant statin users (>50% compliance,
n = 4415) relative to nonusers. Statin use substantially reduced MACE in those with elevated CAC.
HRs for all statin users with CAC values 1–100, 101–400, and 401+ were 0.83 (95% CI: 0.60–1.16),
0.32 (0.21–0.48), and 0.56 (0.34–0.90), respectively. The corresponding HRs for compliant users relative
to nonusers were similar for these groups, but not in the case of CAC = 0. Compliant users with no
CAC experienced modest reduction (HR: 0.66, 95% CI: 0.49–0.88), but the benefit was abrogated for all
users (HR: 1.00, 95% CI: 0.79–1.27). The results illustrate the utility of CAC in identifying patients who
will particularly benefit from statin therapy. The 10-year NNT for statin users with a CAC of 1 to 100
was calculated to be 100, while NNT = 12 was obtained for CAC > 100 [71].
A lack of CAC can be used to rule out statin treatment in low-risk individuals. In a recent study of
13 candidate markers of ASCVD including apolipoprotein B, CAC = 0 and CAC≤ 10 were found to be the
strongest negative risk markers in 5805 older adults (mean age 69 y) [82]. Lastly, an inverse association
has been observed between CAC density and serum magnesium [83]. Serum magnesium inhibits
extracellular calcification, and low serum magnesium is associated with CHD and sudden cardiac death
(HRs: 1.36 and 1.54 for lowest quartile) [84]. The 2018 revision of the ACC/AHA guidelines advise that
CAC can facilitate treatment decisions when risk status is uncertain [85]. The personalized approach of
withholding statins, for example in low-risk elderly patients, has been termed “derisking” [6]. In fact,
the stratification of statin benefits by CAC scores can result in much lower NNTs than when using
the highest risk categories from a traditional risk calculator, see Refs. [70,71,86] (Table 1). One could
argue that a criterion based on CAC score should therefore be added to the four statin benefit groups
originally envisioned by the 2013 ACC/AHA guidelines [87]. An alternative approach would be to
incorporate CAC into the risk calculator. In a study of U.S. and European adults aged 60–96 (mean:
70 y) without ASCVD, replacing a single variable, patient age, with CAC score was shown to improve
traditional models for predicting the rate of incident CHD [88].
The fact that the association of CAC with ASCVD risk remains significant in elderly patients
contrasts with many traditional risk factors [82,88]. The hazard ratio of BMI for myocardial infarction
has been shown to decline rapidly from age 50 to age 70, and similarly for the association of systolic
blood pressure with ischemic stroke and heart failure [89]. In the same study, LDL-C but not HDL-C
remained associated with myocardial infarction up to the study endpoint of age 82.
8. Coenzyme Q and Muscle Function: Role for Supplementation
The mevalonate biosynthetic pathway is responsible for endogenous production of both cholesterol
and ubiquinone, or coenzyme Q10 (CoQ). CoQ is an important antioxidant and functions as an electron
carrier in the mitochondrion responsible for cell respiration. Endogenous levels of CoQ in plasma
and in various organs decline with age [90,91], and decreased CoQ has been implicated in age-related
diseases [92]. A population study in Israel recently associated CoQ supplementation with reduced
odds of SARS-CoV-2 hospitalization (OR: 0.185, 95% CI: 0.06–0.46) [93]. Earlier studies observed that
low levels of plasma CoQ associate with increased mortality in chronic heart failure (CHF) in the
elderly [94,95]. Long-term dietary supplementation with 300 mg/d CoQ in addition to standard CHF
therapy has since been shown to reduce MACE as well as cardiovascular and all-cause mortality in
RCTs of older adults [96,97]. Meta-analysis of 14 RCTs found that CoQ supplementation significantly
decreased mortality (RR: 0.69, 95% CI: 0.50–95) and increased exercise capacity in CHF patients
compared to placebo [68].
Statin drugs are inhibitors of the enzyme HMG-CoA reductase, which catalyzes the rate-limiting
step of converting HMG-CoA into mevalonate. Statin use has been demonstrated to decrease plasma
levels of CoQ in a dose-dependent fashion [94,98,99]. The inverse association between CoQ levels and
heart failure could help explain why statins alone do not decrease the risk of heart failure in elderly
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patients without ASCVD, and offer non-significant benefit in secondary prevention (RR: 0.79, 95% CI:
0.59–1.06) [72].
Mitochondrial function is essential for muscle fitness and maintaining health in old age.
A translational research study by Schirris et al. elucidated the mechanism of statin-induced
myopathy [100]. Using a myoblast cell line, the cyclic lactone forms of the seven statins were
found to more potently induce cytotoxicity and reduce respiration and mitochondrial ATP production
compared to their carboxylic acid equilibrium forms. The off-target mechanism of action involved
up to 84% inhibition of mitochondrial electron transport chain complex III (CIII). CIII is a ubiquinol
oxidase that oxidizes CoQH2 into CoQ, transferring its electrons to complex IV in order to reduce
molecular oxygen. In muscle biopsies of 37 patients with statin-induced myopathy, CIII activity
and ATP production decreased by up to 18% compared to healthy controls [100]. Analogous to an
earlier cell study with simvastatin [101], respiratory inhibition could be prevented by increasing the
endogenous pool of CoQH2, which competes for the same binding site on CIII as the statin lactone. In a
recent study of 571 adults taking atorvastatin, cigarette smoking was found to increase lactonization
via enzyme induction [102]. The study also associated increased age, low BMI, proton pump inhibitors,
and loop diuretics with increased levels of exposure to atorvastatin, factors thought to increase the risk
of statin-associated myotoxicity [102,103].
The observations on muscle function and heart failure would seem to suggest that CoQ should
be coadministered with long-term statin therapy. Well-designed RCTs demonstrate CoQ to be safe
and effective in treating a number of human diseases such as primary CoQ deficiency syndrome,
a rare mitochondrial disease, with a highest possible dose of 1200 mg/d [92,104]. Small clinical
trials of statin and CoQ coadministration provided some early evidence of reducing statin-associated
myopathy [105,106]. A 2018 meta-analysis has since identified 12 RCTs involving 575 patients [107].
Compared with placebo, CoQ supplementation significantly decreased statin-associated muscle pain,
weakness (P = 0.006), cramps, and tiredness (P < 0.001). Despite myalgia being the most common cause
of statin intolerance and medication nonadherence, current clinical guidelines have yet to recommend
routine use of CoQ in statin users [40,85]. The reduced form of CoQ, ubiquinol (CoQH2), is now
being explored as a superior supplement and antioxidant. The ratio of CoQH2 to CoQ has been
shown to decrease with age and is reduced in patients with geriatric diseases, indicative of systemic
oxidative stress [108]. Ubiquinol reverses statin inhibition of CIII [100], and has superior bioavailability
compared to its oxidized form ubiquinone [109–111].
Selenium is an essential antioxidant that is needed for enzymatic reduction of CoQ to its active
form, ubiquinol [112]. The soil content of selenium is low in Europe compared to the U.S. An RCT was
conducted of 443 healthy Swedes aged 70–88 (20% statin users) whom were given placebo or CoQ
capsules 100 mg B.I.D. + selenium tablets 200 µg/d for 4 years [113]. Follow-up results were obtained
for a period of up to 10 years after intervention, and Cox regression analysis was used to measure the
cardiovascular mortality risk [114]. Significant reductions were observed for the treatment group in
cardiovascular mortality (HR: 0.51, 95% CI: 0.36–0.74, P = 0.0003) and plasma NT-proBNP, a biomarker
for heart failure [113,114].
Ubiquinol itself is now produced as a supplement. A small trial was conducted using ubiquinol
600 mg/d, but it failed to demonstrate an effect on myalgia symptoms [115]. Taylor et al. first used
an eight-week double-blind crossover trial to eliminate patients without confirmed statin-associated
myalgia. Only 41 of 120 subjects, who experienced pain on simvastatin and not placebo, and whose
pain resolved within four weeks off treatment, were chosen for inclusion in their subsequent analysis.
Other limitations in the small trial were that a moderate-intensity statin was used and only 32 patients
completed the second crossover treatment and received CoQH2. The authors estimated a sample
of n = 720 would be needed to prove ubiquinol reduces statin myalgia [115]. Large scale RCTs will
ultimately be needed to confirm the protective effect of ubiquinol in statin users. Research in this area
has also been hampered to some extent by the need for an objective means of diagnosing myalgia,
myopathy, and myositis [116].
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9. Primary Prevention in Middle-Age Adults
Given the relative weakness of evidence for the use of statins in primary prevention of ASCVD,
further research is needed to assess the efficacy of statins in middle-aged adults. Unfortunately,
RCTs and meta-analyses of statins across age groups have typically incorporated participants with a
prior history of ASCVD [10,117,118]. One meta-analysis was performed on 11 RCTs involving 65,229
high-risk patients in the use of primary prevention [119]. Statins did not reduce all-cause mortality (RR:
0.91, 95% CI: 0.83–1.01). Using meta-regression, the baseline age of each of the 11 study cohorts was able
to explain 66% of the variation in mortality rate, however. This finding illustrates how confounding
variables can potentially influence our analysis and interpretation of the whole of evidence from clinical
trials. An earlier meta-analysis was conducted of 20 RCTs in which >50% of adult participants had no
history of CHD [120]. In a total of 65,261 patients, statins exhibited small reductions in MACE (RR:
0.85, 95% CI: 0.77–0.95), ASCVD deaths (RR: 0.89, 95% CI: 0.81–0.98), and all-cause mortality (RR: 0.93,
95% CI: 0.87–0.99).
Retrospective analysis of an electronic patient database allows one to examine large
population-level cohorts incorporating specific groups often excluded from RCTs (e.g., poor statin
tolerance), thus evaluating treatment efficacy in real clinical conditions. While statin treatment
guidelines emphasize maximal relative risk reductions, a recent Spanish population study by Garcia-Gil
et al. determined the 5-year NNT for adults aged 35–74 in primary prevention [70]. A total of
617,850 patient records were analyzed from the SIDIAP database. Statins were found to decrease
ASCVD events according to a patient’s 10-year CHD risk category (Table 1). In statin users with >70%
adherence, statins decreased ASCVD in individuals with 10-year risk categories of 7.5–10% (HR: 0.70,
95% CI: 0.54–0.92; NNT = 75) and 10–20% (HR: 0.74, 95% CI: 0.61–0.90; NNT = 62). All-cause mortality
reduction was significant only for individuals with 10–20% risk (HR: 0.73, 95% CI: 0.59–0.91; NNT = 69).
Regardless of CHD risk, no clinically relevant effect size was found for ASCVD or all-cause mortality
in patients with low adherence to therapy [70]. Medication nonadherence is a common problem due to
statin intolerance, and the fraction of study participants achieving adequate reductions in LDL-C is
estimated to range from 20% to 64% [121].
10. Effect of Lipid-Lowering Medication on Lipoprotein Subfractions
Further research is needed to examine the impact of lipid-lowering medications on the relative
proportions of atherogenic lipoprotein particles in the blood. A covalently modified form of LDL,
lipoprotein(a) [Lp(a)], is considerably atherogenic and is observed to be elevated three-fold in CHD
patients [122]. A meta-analysis of seven RCTs involving 29,069 adults revealed statins reduced LDL-C
by a mean of 39% (95% CI: 35–43), while not significantly changing Lp(a) [123]. Baseline and on-statin
levels of Lp(a) were associated with ASCVD risk, with HRs for ≥50 mg/dL (vs. <15 mg/dL) = 1.31
(95% CI: 1.08–1.58) and 1.43 (95% CI: 1.15–1.76), respectively. In contrast with statins, PCSK9 inhibitors
are a new class of monoclonal antibody therapy developed to lower LDL-C. Pooled analysis of
3,278 patients from 10 clinical trials demonstrated that biweekly evolocumab treatment reduced Lp(a)
by 25% [124]. Other studies have found statins to slightly increase the relative proportion of atherogenic
Lp(a) and sdLDL [125,126].
Ongoing research efforts are examining the role of cholesterol in triglyceride-rich lipoproteins
(VLDL, IDL, chylomicron remnants), termed remnant cholesterol. In a Danish population study,
32%, 35%, and 32% of nonfasting plasma cholesterol was contained in remnant lipoproteins, LDL,
and HDL, respectively [127]. Remnant cholesterol has been shown to be one of the best lipid markers for
predicting myocardial infarction and can be easily calculated [128–130]. Relative to the lowering effect
on LDL-C, remnant cholesterol was observed to be reduced by 80% through either statin treatment or
genetic inhibition of HMG-CoA reductase in a metabolomic profiling study [131]. Icosapent ethyl has
been shown to reduce remnant cholesterol by 21% compared to placebo and by 57% when taken in
conjunction with statin therapy [130]. The REDUCE-IT trial examined the role of icosapent ethyl in
reducing the residual cardiovascular risk not addressed by statin treatment [132]. Patients were eligible
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who had been receiving statin therapy, had triglyceride and LDL-C levels of 135–499 (median, 216) and
41–100 (median, 74) mg/dL, respectively, and had established ASCVD or diabetes. Adjuvant treatment
with icosapent ethyl was observed to decrease triglycerides by 18% and reduce ASCVD events (HR:
0.75, 95% CI: 0.68–0.83) compared to statin treatment alone. Other RCTs have associated triglyceride
levels with residual coronary risk [133]. Of note, one fifth of U.S. adults with diabetes have residual
hypertriglyceridemia, despite their LDL-C being well-controlled by statins [134].
Recent guidelines and consensus papers have promoted non-HDL (TC minus HDL-C) for
ASCVD prediction, which is equivalent to LDL and remnant cholesterol combined [40], see also Refs.
11–13 in [129]. Earlier analysis revealed a log-linear association of non-HDL and HDL-C with CHD risk
in 302,430 Europeans and North Americans [41]. Non-HDL correlated strongly with apolipoprotein
B, and the hazard ratios were as least as strong when computed for individuals who did not fast
compared to those who did, further speaking to their ease of measurement. After adjusting for HDL-C
and non-HDL, the association between plasma triglyceride and CHD was abolished [41]. This has led
some to conclude that triglyceride is largely a surrogate clinical marker, and that cholesterol is the
principal lipid deposit within atherosclerotic plaque [129]. The PURE study recently estimated the
population-attributable fractions of ASCVD for 14 behavioral and metabolic risk factors [64]. Non-HDL
was the strongest lipid risk factor for ASCVD (HR: 1.31 highest/lowest tertile, 95% CI: 1.21–1.41).
11. Perspective
Given that ASCVD is a cardiometabolic disorder, an important dimension of statin treatment is
the role of habitual diet. Analysis of 27,886 U.S. adults from 1999 to 2010 indicated that caloric and fat
intake and BMI increased among statin users by 10%, 14% and +1.3, respectively, while not changing in
nonusers [135]. The importance of diet and nutrition must be emphasized during patient medication
counseling. Trimethylamine N-oxide, a metabolite of animal products, has been implicated in arterial
plaque development [136], and plasma levels are a strong risk marker for MACE and all-cause mortality
(pooled RRs: 1.62 and 1.63) [137]. A Mediterranean-style diet low in meat and dairy products has been
reported to reduce the relative risk of MACE and cardiovascular mortality by 30% [138,139]. New lines
of research suggest a synergistic interaction between statin treatment and dietary improvement [140].
In a prospective observational study of secondary prevention in southern Italy (mean age 67.7 ± 10),
statins decreased all-cause and cardiovascular mortality only in patients with an average or high
Mediterranean diet score, and by 50% compared to the control group of non-statin users with low diet
score [141]. Rather than furthering improving blood lipids, a Mediterranean diet was found to reduce
low-grade inflammation in the presence of statins, shedding light on the mechanism of interaction
between diet and mortality benefit.
Statins are increasingly prescribed using a treat-all approach to prevent ASCVD. The broadening
of diagnostic criteria in recent decades has led to their use in low-risk and elderly individuals,
dramatically altering the absolute risk reduction and NNT obtained for MACE and mortality
outcomes [2,7,10,70]. Current clinical guidelines emphasize identifying a patient’s family history
of dyslipidemia. After excluding familial hypercholesterolemia, however, LDL-C or triglycerides
> 90th population percentile associate similarly with CAD risk regardless of family history [142].
Maximal reduction in LDL-C has long been the target of statin therapy. The 2013 ACC/AHA guidelines
referenced an oft-cited 28% reduction in RR per mmol/L reduction in LDL-C [87]. In contrast, a recent
meta-analysis of intensive statin therapy for primary and secondary prevention combined found a
modest RR of 14% for adults whose baseline LDL-C was ≥100 mg/dL [118].
Despite widespread use, current evidence on the benefit effect size does not support the use
of statins for primary prevention in very old adults, in whom the significance of adverse effects is
amplified [6]. The U.S. Preventive Services Task Force concluded that the evidence does not support
statin therapy for primary prevention of ASCVD in adults over 75 [61], consistent with the evidence
presented here for octogenarians. The AGREE II instrument was used to evaluate 33 international
guidelines for ASCVD prevention [143]. Only 18 guidelines were found to provide instructions for
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discontinuation of statins, which were related to general intolerance or poor health rather than age
status. Their findings underscore the lack of a deprescribing tradition and the growing reliance of
practice guidelines on low-level evidence and expert opinion [144]. One French population study of
120,173 statin users aged 75 or older did find an increased risk of ASCVD upon statin discontinuation
(RR: 1.33, 95% CI: 1.18–1.50), however mortality rates were not assessed [145].
12. Conclusions
To predict the benefits and harms of lipid-lowering medications in select individuals, access
to full clinical trial data and new trials incorporating specific patient populations are needed [2,10].
Outcomes data available for specific patient groups and improvements in risk assessment enable
healthcare providers to better to balance the risks and benefits of statin therapy (Table 2). Coenzyme
Q is an effective therapeutic adjuvant for CHF, and supplement formulations may prove of benefit
to older adults experiencing statin-associated myopathy. Better metrics now exist for predicting
ASCVD risk compared to calculated LDL-C, such as the CAC score, which can be used to rule
out treatment in low-risk cases for young and old adults alike. Ultimately, hyper-individualized
approaches employing more accurate risk factors and tools will identify the patients that benefit most
from lipid-lowering therapy.
Table 2. Conclusions, statin benefit groups, and robust markers of cardiovascular risk.
Cardiovascular Risk Factors Contraindications/Adverse Effects
Prior history of ASCVD: statins reduce mortality and
ASCVD in secondary prevention [72,76].
Lack of benefit in primary prevention over age
75 without diabetes [69,72]. Derisk at age 65 if no risk
factors [6,62].
CAC = 0 and ≤10 are negative risk markers in old and
young adults [81,82]. CAC > 100 may be considered a
statin benefit group: 10-year NNT = 12 [71].
Myopathy/osteoporosis/new-onset diabetes at high
doses; avoid canagliflozin (see Introduction) [11].
Statins modestly reduce ASCVD in primary
prevention diabetes patients aged 75–84: 1-year
NNT = 164 [69].
Coenzyme Q supplementation improves health
outcomes [68,107,114].
Non-HDL (LDL particle number + remnant
cholesterol) is more predictive than LDL-CF [64,129].
Residual cardiovascular risk persists after LDL-C
controlled by statins alone [133].
2013 pooled cohort equations overestimate 10-year
ASCVD risk: increase 7.5% risk threshold to 10% for
primary prevention [6,55,61].
Healthy diet found necessary for mortality benefit of
statins in secondary prevention [141].
Abbreviation: LDL-CF, traditionally calculated low-density lipoprotein cholesterol (Friedewald equation).
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